A 10-year experience with combined modality therapy for stage III small cell lung carcinoma

Jacobs, Renee H.; Greenburg, A. Gerson; Bitran, Jacob D.; Hoffman, Philip C.; Albain, Kathy S.; Desser, Richard K.; Potkul, Laurel A.; Golomb, Harvey M.

doi:10.1002/1097-0142(19861115)58:10<2177::aid-cncr2820581003>3.0.co;2-o

Cited by 17 publications

(3 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The present study summarizesour two therapeutic clinical trials which were conducted between 1981 and 1987. Our CR rate (48%) and median survival time (17.3 months for LD, ll.3 months for ED) were considerably preferable compared with those in other series (8,13,17) and those being documented as "the state of the art" in the first IASLC Workshop of SCLC (16). With a 4.7-to ll-year follow-up, ll(14%) of 76 patients with LD and two (3% ) of72 patients with ED actually survived beyond 4.7 years.…”

Section: Discussionmentioning

confidence: 60%

Long-Term Results of Combination Chemotherapy with or without Irradiation in Small Cell Lung Cancer: A 5- to 11-Year Follow-Up.

Ohnoshi

Hiraki

Ueda³

et al. 1993

Intern. Med.

View full text Add to dashboard Cite

patients with newly diagnosed small cell lung cancer (SCLC) were treated using combination chemotherapy with or without thoracic irradiation and prophylactic cranial irradiation (PCI) in a series of cooperative therapeutic trials. With a minimumfollow-up of 4.7 years, 13 (9%) patients survived and were free of SCLC. These included ll (15%) of 76 patients with limited disease and two (3%) of 72 patients with extensive disease. Three died without any evidence of SCLC(one each from second leukemia, non-small cell lung cancer, and unrelated disease). The remaining 10 (7%) patients are currently alive and free of SCLCbeyond 4.7 years. Since late relapse beyond 5 years is a very rare event, these patients may have been cured. However, late toxicity of PCI must be kept in mind. Three amongthe 10 patients have suffered from neuropsychologic symptoms of varying degrees in severity. Although the long-term survival rate is a benchmark in the treatment of SCLC, modifications of therapy that may potentially avoid such toxicities should be considered hereafter.

show abstract

Section: Discussionmentioning

confidence: 60%

Long-Term Results of Combination Chemotherapy with or without Irradiation in Small Cell Lung Cancer: A 5- to 11-Year Follow-Up.

Ohnoshi

Hiraki

Ueda³

et al. 1993

Intern. Med.

View full text Add to dashboard Cite

show abstract

“…Small-cell lung carcinoma (SCLC) is a highly malignant disease with a 5-year survival of 5 to 12% (Jacobs et al, 1986). Despite frequent initial complete responses after combined chemotherapy, almost all patients relapse with metastases in distant organs such as the liver, bone-marrow and brain.…”

mentioning

confidence: 99%

Tumor‐cell killing by MAbs against fucosyl GM1, a ganglioside antigen associated with small‐cell lung carcinoma

Brezicka

Holmgren

Kalies

et al. 1991

Intl Journal of Cancer

View full text Add to dashboard Cite

Monoclonal antibodies (MAbs) reactive with the ganglioside fucosyl GM1 (Fuc-GM1), an antigen associated with small-cell carcinoma of the lung (SCLC), were tested for their ability to mediate tumor-cell killing in vitro in conjunction with humoral and cellular effectors and to inhibit tumor engraftment in nude mice in vivo. MAbs F12 and F15, both IgG3k, induced human complement-mediated cytolysis of 3 Fuc-GM1-expressing tumor cell lines: one rat hepatoma cell line, H4-II-E, and 2 human SCLC cell lines, NC1 H69 and NC1 H128. F12 and F15 also induced ADCC of these cell lines in the presence of either murine or human effector cells. Addition of sub-cytolytic amounts of fresh human serum as complement source resulted in enhanced ADCC induced by MAb F12 (IgG3). Also a Fuc-GM1-reactive MAb of IgM isotype, F9, was able to induce such complement-aided ADCC (CADCC). F12 and F15 both proved to effectively inhibit engraftment of H4-II-E tumors in nude mice. A single dose of a modest amount (40 micrograms) of MAb conferred 65 to 100% protection against development of tumors. Our results demonstrate that Fuc-GM1 can act as a target antigen on tumor cells for specific immunotherapy in vitro and in a mouse model in vivo. Complement and murine and human mononuclear effector cells were effective mediators of tumor cytolysis in vitro in the presence of murine Fuc-GM1-reactive MAbs. Our results also suggest that humoral and cellular effectors may co-operate in specific tumoricidal reactions and that these may be induced by antibodies of both IgG and IgM isotypes.

show abstract

“…Fewer have addressed the question of prognostic factors for disease-free survival in excess of 5 years. [18][19][20][21][22][23] To assess the curability of SCLC and to identify factors which have prognostic significance both for overall survival duration and for at least 5-year disease-free survival,…”

mentioning

confidence: 99%

Predictors of 5-year survival and curability in small cell lung cancer

Crown

Chahinian

Jaffrey

et al. 1990

Cancer

View full text Add to dashboard Cite

A retrospective analysis of various characteristics in 81 small cell lung cancer patients treated at the Mount Sinai Medical Center, New York, from 1974 to 1982 was carried out to identify factors which had prognostic significance for long-term survival, defined as actual disease-free survival for at least 5 years from initiation of therapy. Six patients, five female patients (16.7%) and one male patient (2%), including four limited disease (9.7%) and two extensive disease patients (5%) were long-term survivors (73 to 96+ months from onset of therapy), and among them three remain alive and disease-free at 84, 84, and 96 months from first treatment, respectively. Although several factors, including sex, stage of disease (limited versus extensive), and occurrence of herpes zoster predicted overall survival duration, female sex and an occurrence of herpes zoster were the only variables which were statistically significantly related to 5-year survival. Herpes zoster was a relatively late occurrence whereas female sex was an independent positive prognostic factor.

show abstract

A 10-year experience with combined modality therapy for stage III small cell lung carcinoma

Cited by 17 publications

References 18 publications

Long-Term Results of Combination Chemotherapy with or without Irradiation in Small Cell Lung Cancer: A 5- to 11-Year Follow-Up.

Long-Term Results of Combination Chemotherapy with or without Irradiation in Small Cell Lung Cancer: A 5- to 11-Year Follow-Up.

Tumor‐cell killing by MAbs against fucosyl GM1, a ganglioside antigen associated with small‐cell lung carcinoma

Predictors of 5-year survival and curability in small cell lung cancer

Contact Info

Product

Resources

About